MDB Capital Holdings Provides Third Quarter 2026 Update
Key Highlights
- ➤Fee income increased 96% to $4.2 million for nine months ended September 30, 2026
- ➤eXoZymes (EXOZ) selected Curia as first commercial-scale manufacturing partner for NCT
- ➤Paulex Bio registered a first-in-human Phase 1/2a trial of PAL-119
- ➤PatentVest pursuing financing to expand its client base and become independent in 2027
- ➤Cash and cash equivalents totaled $8.3 million as of September 30, 2026
Expert Statements
Christopher Marlett, CEO and co-founder of MDB Capital
“MDB is focusing its resources on advancing Public Ventures, PatentVest, eXoZymes and Paulex Bio toward their next milestones while working to reduce operating costs and continuing to pursue select new public venture opportunities.”
Christopher Marlett, CEO and co-founder of MDB Capital
“MDB’s objective is to realize value from these businesses for shareholders as they reach key milestones.”
Addison, TX, Nov. 17, 2026 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching early-stage technology companies, today provides a business update for the quarter ended September 30, 2026, and subsequent developments. MDB is focusing its resources on advancing Public Ventures, PatentVest, eXoZymes and Paulex Bio toward their next milestones while working to reduce operating costs and continuing to pursue select new public venture opportunities.
Business and Strategic Highlights * MDB focused on moving four validated Big Ideas toward a value inflection point: * Public Ventures. MDB is in discussions with potential strategic and capital partners to expand the reach of Public Ventures’ self-clearing platform, including a potential launch independent of MDB. * PatentVest. Our innovative IP law firm is pursuing financing to grow its client base at scale and expand its marketing efforts in preparation to become an independent company in 2027. * eXoZymes (Nasdaq: EXOZ). eXoZymes selected Curia as its first commercial-scale manufacturing partner to support technology transfer and scale-up of NCT as it advances toward commercial manufacturing along with announcing new compounds with large market potential. * Paulex Bio. Paulex announced the registration of a first-in-human Phase 1/2a trial of PAL-119, an investigational oral drug candidate targeting the root cause of Type 1 and Type 2 diabetes. The study is designed to evaluate safety and tolerability and explore beta cell expansion.
Get started
Create a free account to read the full story.
